Renal Outcome with Empagliflozin in non-diabetic Chronic Kidney Disease Patients: A Randomized Control Trial

Change in the baseline of eGFR. This will be measured according to the EPI-CKD equation. It will be done by a blood test.

Chronic kidney disease is a serious public health problem as it is one of the major causes of hospitalization worldwide. Despite receiving medical treatment, the outcomes remain either fast progression to dialysis or transplantation. The findings of the EMPEROR Reduced trial and DAPA CKD trials support our rationale to further explore the effects of the drug beyond the diabetic patients. we would further like to explore the effects on just CKD patients and how does this drug affect the progression of CKD. It is hypothesized that by including this drug with the standard of treatment, it will slow down the progression of Chronic kidney disease to next stage.